By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
GMJ NewsGMJ NewsGMJ News
  • Latest News
    • GMJ Briefs
  • Podcast & Media
    • Podcast Episodes
    • GMJ Audio
    • GMJ Videos
  • Research Digest
    • New Studies
    • Georgian Research
    • Data & Numbers
  • Policy & Systems
    • Health Policy
    • Quality & Safety
    • Migration & Health
    • Global Health
  • Practice
    • Clinical Updates
    • Case Discussions
    • Pharmacy & Prescribing
    • Ingredients A-Z
  • Perspectives
    • Editorial
    • Explainers
    • Voices
    • Letters
  • GMJ Articles
    • Vol. 1 Issue 2 (2026)
    • Vol. 1 Issue 1 (2026)
    • Pre-Launch Articles (2025)
  • Read the Journal →
  • About GMJ News
Notification Show More
Font ResizerAa
GMJ NewsGMJ News
Font ResizerAa
  • Latest News
    • GMJ Briefs
  • Podcast & Media
    • Podcast Episodes
    • GMJ Audio
    • GMJ Videos
  • Research Digest
    • New Studies
    • Georgian Research
    • Data & Numbers
  • Policy & Systems
    • Health Policy
    • Quality & Safety
    • Migration & Health
    • Global Health
  • Practice
    • Clinical Updates
    • Case Discussions
    • Pharmacy & Prescribing
    • Ingredients A-Z
  • Perspectives
    • Editorial
    • Explainers
    • Voices
    • Letters
  • GMJ Articles
    • Vol. 1 Issue 2 (2026)
    • Vol. 1 Issue 1 (2026)
    • Pre-Launch Articles (2025)
  • Read the Journal →
  • About GMJ News
Follow US
GMJ News > Drugs A-Z > General > Vortioxetine

Vortioxetine

GMJ
Last updated: 02/06/2026 14:30
By
Prof. Giorgi Pkhakadze
Share
5 Min Read
SHARE
3 min read|665 words

What is Vortioxetine?

Vortioxetine is an atypical antidepressant medication that belongs to a class of drugs known as serotonin modulators and stimulators. It is primarily prescribed to treat major depressive disorder in adults. Unlike traditional selective serotonin reuptake inhibitors (SSRIs), vortioxetine works through multiple mechanisms to affect serotonin activity in the brain.

Uses

Major Depressive Disorder: The primary FDA-approved use for vortioxetine is treating major depressive disorder in adults, helping to improve mood, energy levels, and overall functioning.

Cognitive Symptoms of Depression: Clinical studies suggest vortioxetine may be particularly beneficial for addressing cognitive symptoms associated with depression, such as difficulty concentrating, memory problems, and mental processing speed.

Treatment-Resistant Depression: Healthcare providers may prescribe vortioxetine when other antidepressants have not been effective or have caused intolerable side effects.

Submit Your Paper
GMJ_Submit_Banner

Maintenance Therapy: Once depression symptoms improve, vortioxetine may be continued long-term to prevent relapse and maintain mental health stability.

How it works

Vortioxetine works through a complex mechanism called multimodal activity, affecting serotonin in several different ways simultaneously. It blocks serotonin reuptake like traditional SSRIs, but also acts as an antagonist at certain serotonin receptors while stimulating others. This unique combination of actions may explain why it appears to have benefits for both mood and cognitive function in depression.

Side effects

Common side effects include:

  • Nausea and vomiting
  • Diarrhea or constipation
  • Dizziness
  • Dry mouth
  • Sexual dysfunction
  • Abnormal dreams or sleep disturbances
  • Fatigue
  • Itching or skin reactions

Serious side effects to watch for:

  • Suicidal thoughts or behavior, especially in young adults
  • Serotonin syndrome (agitation, confusion, rapid heart rate, high fever)
  • Abnormal bleeding, particularly when combined with blood thinners
  • Severe allergic reactions
  • Manic episodes in people with bipolar disorder

Warnings and precautions

Black Box Warning: Vortioxetine carries an FDA black box warning about increased risk of suicidal thoughts and behaviors in children, adolescents, and young adults under 25, particularly during the first few months of treatment.

Pregnancy Considerations: Vortioxetine is classified as pregnancy category C, meaning potential benefits may warrant use despite possible risks to the fetus. It may cause withdrawal symptoms in newborns if used during the third trimester.

Liver Function: While no dose adjustment is typically needed for mild to moderate liver impairment, patients with severe liver disease should be monitored closely.

Bipolar Disorder Screening: Patients should be screened for bipolar disorder before starting vortioxetine, as antidepressants can trigger manic episodes in susceptible individuals.

Gradual Discontinuation: Vortioxetine should be tapered gradually rather than stopped abruptly to minimize withdrawal symptoms such as dizziness, nausea, and flu-like symptoms.

Interactions

MAO Inhibitors: Dangerous serotonin syndrome can occur when combined with monoamine oxidase inhibitors; requires at least 14-day washout period between medications.

Other Serotonergic Drugs: Increased risk of serotonin syndrome when combined with other antidepressants, triptans, tramadol, or St. John’s wort.

Blood Thinners: Warfarin, aspirin, and NSAIDs may increase bleeding risk when used with vortioxetine due to effects on platelet function.

Strong CYP2D6 Inhibitors: Medications like bupropion, fluoxetine, and quinidine can increase vortioxetine levels, potentially requiring dose reduction.

CYP Inducers: Rifampin, carbamazepine, and phenytoin may decrease vortioxetine effectiveness by increasing its metabolism.

Diuretics: May increase risk of hyponatremia (low sodium levels), particularly in elderly patients.

Alcohol: Should be avoided as it may worsen depression and increase drowsiness.

Check interactions with the GMJ Interaction Checker

Dosage

The typical starting dose for adults is 10 mg once daily, taken with or without food. The dose may be increased to 20 mg daily if needed and tolerated, or reduced to 5 mg daily if side effects occur. For patients who are poor metabolizers of CYP2D6 or taking strong CYP2D6 inhibitors, the maximum recommended dose is 10 mg daily. Elderly patients may require lower doses due to increased sensitivity. All dosage adjustments should be made gradually and only under the guidance of a healthcare provider who can monitor response and side effects.

Sources: FDA DailyMed drug labels (public domain), BNF, WHO Essential Medicines List. This article is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before starting or stopping any medication.

Cite this page

GMJ News Desk. "Vortioxetine." GMJ News — Georgian Medical Journal, 2 June 2026. https://news.gmj.ge/drug/vortioxetine/

CC BY 4.0This work is licensed under Creative Commons Attribution 4.0 International (CC BY 4.0). You are free to share and adapt this content with attribution to GMJ News (news.gmj.ge).

Was this article helpful?

Share This Article
Facebook LinkedIn Bluesky Copy Link Print
GMJ
ByProf. Giorgi Pkhakadze
Follow:
Prof. Giorgi Pkhakadze, MD, MPH, PhD, is Editor-in-Chief of the Georgian Medical Journal and Chair of the Public Health Institute of Georgia (PHIG). He is Professor and Head of the Department of Social and Behavioural Sciences at David Tvildiani Medical University, and Secretary/Treasurer of the UEMS Section of Public Health. ORCID: 0000-0001-7609-4515.

Submit Your Paper →

Georgia's peer-reviewed open-access medical journal. No APC until January 2027.
Submit Manuscript →
FDA’s Pazdur Calls for Agency Restructuring Amid China Competition and Internal Upheaval

FDA's Rick Pazdur calls for fundamental agency restructuring following internal disruption, citing…

Revolution Medicines Ships Experimental Pancreatic Cancer Drug Under Early Access

Revolution Medicines begins expanded access program for daraxonrasib targeting KRAS G12C mutations.…

NHS Patient Watchdog Abolition Sparks Concerns Over Health Service Accountability

Local councils warn that government plans to abolish NHS patient watchdogs will…

Submit Your Paper to GMJ

No APC until January 2027.
Submit Manuscript →

You Might Also Like

Oxybutynin

By
Prof. Giorgi Pkhakadze
02/06/2026

Tiotropium

By
Prof. Giorgi Pkhakadze
02/06/2026

Ergotamine

By
Prof. Giorgi Pkhakadze
02/06/2026

Vitamin B9 (Folate)

By
Prof. Giorgi Pkhakadze
02/06/2026
Facebook Twitter Youtube Instagram
Company
  • Privacy Policy
  • Contact US
  • GMJ Journal
  • Submit Manuscript
  • Editorial Team
  • Register at GMJ
  • Terms of Use

Subscribe to GMJ News — Click here

Join Community
© 2026 Georgian Medical Journal (GMJ). Published by the Public Health Institute of Georgia (PHIG). All rights reserved.
Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?

Not a member? Sign Up